Chiasma's private decision
Why Chiasma and VCs opted for a $70M series E rather than an IPO
Chiasma Inc. profiles as a potential IPO candidate with a late-stage asset on the verge of registration. But MPM Capital's Todd Foley told BioCentury that the recent unexpected return of commercial rights for its octreotide acetate to treat acromegaly meant the timing wasn't right.
Instead, Chiasma's investors